Business
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical
About this update from Medicus Pharma Ltd.
[{"type":"text","content":"Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (\"Medicus\" or the \"Company\"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that Babar K. Rao, MD, FAAD, an internationally recognized academic dermatologist and Principal Investigator of the SKNJCT-003 Phase 2 clinical study, will join the Company’s leadership team during a business update webcast on March 26, 2026 at 11:30 a.m. Eastern time. The SKNJCT-003 study represents a randomized, double-blind Phase 2 clinical trial designed to rigorously evaluate the therapeutic contribution of doxorubicin delivered through the SkinJect® microneedle platform in patients with nodular basal cell carcinoma. The update call will follow the filing of the Company’s Form 10-K for fiscal year 2025, expected after market close on March 25, 2026. During the call, Dr. Rao will provide clinical interpretation and independent investigator perspective on the recently reported positive dataset from SKNJCT-003. Basal cell carcinoma (BCC), a highly immunogenic tumor, is the most common cancer worldwide, and SkinJect is designed to provide a minimally invasive treatment option that could potentially reduce the need for surgical excision. The 73% clinical clearance observed in the 200-µg treatment cohort suggests that approximately three (3) out of four (4) treated lesions may achieve visual tumor clearance, potentially allowing many patients to avoid immediate surgical intervention. Dr. Rao is widely recognized as a leading academic dermatologist, dermatopathologist, and clinical investigator in skin oncology. He currently serves as: Professor of Dermatology and Pathology, Rutgers Robert Wood Johnson Medical SchoolClinical Associate Professor of Dermatology, Weill Cornell Medical CollegeAdjunct Professor of Dermatology, California Health Sciences University Dr. Rao is a board-certified dermatologist and Fellow of the American Academy of Dermatology (FAAD) with decades of experience in dermatologic oncology, dermatopathology, and clinical research. He completed his dermatology residency an...